Previous 10 | Next 10 |
2023-08-10 10:32:36 ET Pulmatrix press release ( NASDAQ: PULM ): Q2 GAAP EPS of -$1.04. Revenue of $1.84M (+38.3% Y/Y). For further details see: Pulmatrix GAAP EPS of -$1.04, revenue of $1.84M
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Subject enrollment for the Phase 2b study of PUR1900 is ongoing with five additional sites added during Q2, totaling thirteen active sites to date in four countries, and top...
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine PR Newswire LEXINGTON, Mass. , July 11, 2023 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: P...
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society PR Newswire LEXINGTON, Mass. , June 15, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative i...
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention PR Newswire Presentation will showcase Company's patented iSPERSE™ technology and positive topline results from Phase 1 study of PUR3100 for acute migraine ...
2023-05-12 11:45:18 ET Pulmatrix press release ( NASDAQ: PULM ): Q1 GAAP EPS of -$1.22. Revenue of $1.5M (+29.3% Y/Y). For further details see: Pulmatrix GAAP EPS of -$1.22, revenue of $1.5M
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Patient dosing initiated for Phase 2b study of PUR1900 for ABPA Phase 1 study of PUR3100 for migraine achieves positive topline results $30.8 million in c...
Pulmatrix Supports World Asthma Day 2023 PR Newswire LEXINGTON, Mass. , May 2, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central...
2023-03-30 09:58:44 ET Pulmatrix press release ( NASDAQ: PULM ): FY GAAP EPS of -$5.46. Revenue of $6.1M (+17.3% Y/Y). Research and development expense was $18.2 million for the year ended December 31, 2022, as compared to $15.4 million for the year ended December 31, ...
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update PR Newswire PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in ...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update PR Newswire 2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026 3 rd amendment to Cipla partnership resulted in the wind down o...
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives PR Newswire Cipla to take sole responsibility for development of PUR1900, refocu...
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four countries; topline...